Ultragenyx Pharmaceutical
RARE | NASDAQ
$15.90
-$0.18 (-1.12%)
At close: Nov 16, 2026, 4:00 PM ET
$15.85
-$0.05 (-0.31%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Ultragenyx Pharmaceutical Company Profile
Company profile explainedCompany Profile
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.
Key Executives
| Name | Position |
|---|---|
| Emil D. Kakkis | Founder, President, Chief Executive Officer & Director |
| Howard Horn | Executive Vice President of Corporate Strategy & Chief Financial Officer |
| Karah Herdman Parschauer | Chief Legal Officer & Executive Vice President of Corporate Affairs |
| Aaron Olsen | Senior Vice President of Corporate Strategy & Finance |
| Dennis Karl Huang | Chief Technical Operations Officer and Executive Vice President of Gene Therapy Operations |
| Eric Crombez | Chief Medical Officer & Executive Vice President |
| Erik Harris | Executive Vice President & Chief Commercial Officer |
| Ernie W. Meyer | Chief Human Resources Officer & Executive Vice President |
| John Richard Pinion | Chief Quality Operations Officer & Executive Vice President of Translational Sciences |
| Theodore A. Huizenga | Senior Vice President, Corporate Controller & Principal Accounting Officer |
| Vimal Srivastava | Senior Vice President of Business Development & Alliance Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 20, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Oct 19, 2026 | 4 | Filing |
| Oct 19, 2026 | 8-K | Current Report |
| Oct 14, 2026 | 8-K | Current Report |
| Oct 07, 2026 | 8-K | Current Report |
| Sep 17, 2026 | 8-K | Current Report |
| Sep 15, 2026 | 4 | Filing |
| Sep 08, 2026 | 4 | Filing |
| Sep 02, 2026 | 8-K | Current Report |
Ultragenyx Pharmaceutical
| Country | United States |
| IPO Date | Jan 31, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,371 |
| CEO | Emil D. Kakkis |
Contact Details
60 Leveroni Court Novato,
California 94949 United States
Stock Details
| Ticker Symbol | RARE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001515673 |
| CUSIP Number | 90400D108 |
| ISIN Number | US90400D1081 |
| SIC Code | 2834 |
Recent News
- 5 days ago / seekingalpha.comUltragenyx: Gene Therapies Must Show, Not Tell, Initiating Hold
- 5 days ago / globenewswire.comUltragenyx to Participate at Investor Conferences in London
- 13 days ago / seekingalpha.comUltragenyx: Still Lacking Appeal Despite 'Commercial-First' Pivot
- 13 days ago / seekingalpha.comUltragenyx Pharmaceutical Inc. (RARE) Q3 2026 Earnings Call Transcript
- 13 days ago / marketbeat.comWhat Ultragenyx Pharmaceutical (RARE) Said on Its Q3 Earnings Call
- 13 days ago / zacks.comUltragenyx (RARE) Reports Q3 Loss, Lags Revenue Estimates
- 13 days ago / zacks.comCompared to Estimates, Ultragenyx (RARE) Q3 Earnings: A Look at Key Metrics
- 13 days ago / globenewswire.comUltragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027
- 20 days ago / globenewswire.comUltragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate Update
- 20 days ago / prnewswire.comAMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026
Add to Watchlist
Select watchlists to add or remove RARE